Piper Sandler Reaffirms Their Buy Rating on NovoCure (NVCR)
Piper Sandler analyst Jason Bednar maintained a Buy rating on NovoCure (NVCR – Research Report) today and set a price target of $28.00.
NovoCure’s Growth Potential Boosted by FDA Approval and Market Expansion
Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...
Buy Rating Affirmed for NovoCure as FDA Approval Expands Optune’s Market Potential
Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target ...
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...
Yahoo Finance17d
Novocure to Report Third Quarter 2024 Financial Results
ROOT, Switzerland, October 01, 2024--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial ...
Seeking Alpha9d
NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM
NovoCure's TTFields showed mixed clinical results in NSCLC, with minor overall survival improvement, questioning its broader adoption beyond glioblastoma. Financially, NovoCure remains strong with ...
The Bakersfield Californian17d
Novocure to Report Third Quarter 2024 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference ...